By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asuragen today announced that it has received US Food and Drug Administration clearance of its cGMP manufactured sample collection and cellular RNA preservation device.

The device called RNARetain was first cleared by FDA in 2007 in conjunction with Agendia's MammaPrint breast cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.